Alar Pharmaceuticals Inc. (TPEX:6785)

Market Cap	8.75B
Revenue (ttm)	5.82M
Net Income (ttm)	18.17M
Shares Out	66.80M
EPS (ttm)	0.27
PE Ratio	481.61
Forward PE	n/a
Dividend	0.25 (0.19%)
Ex-Dividend Date	n/a

Volume	74,277
Average Volume	261,115
Open	131.50
Previous Close	131.00
Day's Range	131.50 - 137.00
52-Week Range	122.50 - 380.00
Beta	0.13
RSI	40.37
Earnings Date	May 9, 2025

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 22
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6785

Financial Performance

In 2024, Alar Pharmaceuticals's revenue was 5.82 million, a decrease of -98.76% compared to the previous year's 469.27 million. Earnings were 18.17 million, a decrease of -95.25%.